IceCure Medical (NASDAQ:ICCM) Issues Earnings Results, Beats Expectations By $0.01 EPS

IceCure Medical (NASDAQ:ICCM) posted its quarterly earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01, Yahoo Finance reports. IceCure Medical had a negative net margin of 444.30% and a negative return on equity of 101.66%. The firm had revenue of $1.01 million for the quarter, compared to analyst estimates of $0.90 million. During the same quarter in the previous year, the business posted ($0.09) earnings per share.

IceCure Medical Stock Down 4.0 %

NASDAQ:ICCM traded down $0.03 during trading hours on Thursday, hitting $0.72. 407,110 shares of the company’s stock traded hands, compared to its average volume of 544,774. IceCure Medical has a twelve month low of $0.52 and a twelve month high of $1.57. The firm has a market cap of $32.71 million, a P/E ratio of -2.26 and a beta of 0.57. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.88 and a current ratio of 3.39. The stock’s fifty day moving average price is $0.72 and its two-hundred day moving average price is $1.03.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright dropped their price target on IceCure Medical from $3.00 to $2.50 and set a “buy” rating on the stock in a research note on Wednesday.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.